314

  • Internet ҳавола
  • DOI
  • UzSCI тизимида яратилган сана 29-04-2020
  • Ўқишлар сони 282
  • Нашр санаси 07-10-2019
  • Мақола тилиRus
  • Саҳифалар сони67-71
Калит сўзлар
Ўзбек

 Gepatit C virusi tanadagi bir qator zararlanishlarni keltirib chiqaradi, 
shu  jumladan  jigarni  ham  zararlaydi.  Ushbu  maqolada  lipid  metabolizmining 
buzilishi  deb  ataladigan  virusli  gepatit  C  bilan  zararlanganlarda  uchraydigan 
muammolardan  biri  muhokama  qilinadi.  Tadqiqotning  asosiy  mazmuni  qonning 
lipidlar  spektri  (umumiyxolesterin  (xolesterin),  yuqori  zichlikda  gilipoproteinlar 
(HDL), juda past zichlikdagilipoproteinlar (VLDL), triglitseridlar (TG)) niqonning 
biokimyoviy tekshiruvlari bilan aniqlash orqali tahlil qilishdir. Surunkali gepatit C 
bilan  og'rigan  bemorlarda  xolesterolning  ko'payishi  va  uning  aterogen 
subfraktsiyalari ko'rinishidagi lipid metabolizmining umumiy buzilishi abdominal 
semizlikka olib keladi. 

English

Hepatitis C virus causes a number of lesions in the body, including 
the  liver  itself.  This  article  addresses  one  of  the  problems  encountered  in  viral 
hepatitis C, the so-called lipid metabolism disorder. The main content of the study 
is  the  analysis  of  determining  the  levels  of  the  lipid  spectrum  (total  cholesterol 
(cholesterol),  high  density  lipoproteins  (HDL),  very  low  density  lipoproteins 
(VLDL),  triglycerides  (TG))  of  the  blood,  by  biochemical  blood  tests. Common 
lipid  metabolism  disorders  in  the  form  of  an  increase  in  cholesterol  and  its 
atherogenicsubfractions in patients with chronic hepatitis C leads to an abdominal 
obesity.

Муаллифнинг исми Лавозими Ташкилот номи
1 Xikmatullayeva A.S.
2 Boqiyeva S.R.
3 Saydivaliyeva K.S.
Ҳавола номи
1 1. Бацков С.С. Гастроэнтерология и гепатология.Учебное пособие/ С.С. Бацков,А.Н. Беляев, А.В. Гордиенко и др. – СПб: Политехника сервис, 2014.–260 с. 2. Гейвандова Н.И., Ягода А.В., Гурницкая М.В., Первушин Ю.В. Вирус-ассоциированные нарушения липидного обмена при хроническом гепатите С. Клиническая гепатология. 2007, 3(4): 25-28; 3. Семендяева М.Е. Неалкогольная жировая болезнь печени как медицинская и социальная проблема. Клиническая практика. 2012, 2: С.71-80; 4. Ascione A., Tartaglione T., Di Costanzo G.G. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 2007; 39(Suppl. 1): 4–7; 5. Chung W.J. Chronic hepatitis C and insulin resistance Korean J. Gastroenterol. 2012; 59(4): 268-274; 6. Cobbold J.F., Cox I.J., Brown A.S. et al. Lipidprofilingofpre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. Hepatol. Res. 2012; 42(7): 714-720; 7. Daniel J.F., Mohamed L.H., Mathieu L., et al. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. Viruses. 2013; 5: 1292-1324; 8. Hwang S.J., Lee S.D. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J. Gastroenterol. Hepatol. 2011; 26(Suppl 1): 96-101; 9. Moucari R., Asselah T., Cazals-Hatem D. et al .Insulinresistancein chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134: 416-423; 10. Patton H.M., Patel K., Behling C. et al. Theimpactofsteatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004; 40: 484-490; 11. Perlemuter G., Sabile A., Letteron P. et al. Hepatitis C viruscore protein inhibits microsomal triglyceride transfer activity and very low density lipoprotein secretion: a model of viral’ related steatosis. Fed. Amer. Soc. Exp. Biol. J. 2002; 16: 185–194.
Кутилмоқда